GCP
PHIO icon

GSA Capital Partners’s Phio Pharmaceuticals PHIO Stock Holding History

GSA Capital Partners’s Portfolio PHIO Stock Details PHIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,864
Closed -$24K – 2073
2026
Q1 		$24K Buy
+19,864
New +$22.7K ﹤0.01% 1639
2021
Q2 		– Sell
-1,225
Closed -$355K – 1534
2021
Q1 		$355K Buy
1,225
+286
+30% +$95.1K 0.06% 549
2020
Q4 		$273K Buy
939
+742
+377% +$188K 0.04% 797
2020
Q3 		$46K Buy
+197
New +$50.1K 0.01% 1189

Other funds holding PHIO

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

GSA Capital Partners's PHIO Position: Q2 2026 in Review

GSA Capital Partners sold out of Phio Pharmaceuticals (PHIO) in Q2 2026, closing a stake of 19,864 shares — an estimated $24K sold.

GSA Capital Partners first reported a position in PHIO in Q3 2020 and held it in 4 quarters. The position peaked at $355K in Q1 2021. 24 funds tracked by Wall St. Rank hold PHIO as of Q2 2026.

  • GSA Capital Partners reported no remaining Phio Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • GSA Capital Partners sold 19,864 Phio Pharmaceuticals shares in Q2 2026, an estimated $24K.
  • GSA Capital Partners first reported a position in Phio Pharmaceuticals in Q3 2020 and held it in 4 quarters.
  • GSA Capital Partners's Phio Pharmaceuticals position peaked at $355K in Q1 2021.
  • 24 funds tracked by Wall St. Rank held Phio Pharmaceuticals as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.